US CRADAs AND INDUSTRY FEARS OF PRICE CONTROL
CRADAs AND INDUSTRY FEARS OF PRICE CONTROL
The US National Institutes of Health "has no doubt" that companies will not accept the risks of investing large sums in the development of a government product, if their freedom to realize a profit could be restricted, according to Bruce Chabner, director of the division of cancer treatment at the NCI.
They are not willing to put their corporate fate in the hands of a government-appointed committee of experts, he testified before a House Small Business regulation subcommittee hearing, chaired by Ron Wyden. "There are less risky ways for companies to make a profit," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze